Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Associated With Mebendazole Use

IF 3.3 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Ida M. Heerfordt, Espen Jimenez-Solem, Magnus Middelboe, Rasmus Huan Olsen, Henrik Horwitz
{"title":"Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Associated With Mebendazole Use","authors":"Ida M. Heerfordt,&nbsp;Espen Jimenez-Solem,&nbsp;Magnus Middelboe,&nbsp;Rasmus Huan Olsen,&nbsp;Henrik Horwitz","doi":"10.1111/bcpt.70086","DOIUrl":null,"url":null,"abstract":"<p>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal conditions, most often caused by adverse reactions to medication [<span>1</span>]. They are characterized by widespread skin necrosis and detachment of the epidermis [<span>1</span>]. The conditions are considered part of a disease spectrum, differentiated primarily by the extent of skin involvement [<span>1</span>]. It is accepted that the triggering medication is generally used within 3 months before symptom onset [<span>1</span>].</p><p>Mebendazole, a commonly used anthelmintic in both children and adults, has rarely been associated with SJS and TEN, primarily through isolated case series [<span>2</span>]. Mebendazole acts by binding to a subunit of helminthic tubulin, inhibiting microtubule formation and thereby disrupting essential cellular processes [<span>3</span>]. While patient labels for mebendazole cite occurrences of SJS and TEN as rare, listed as occurring in between 1 in 10 000 and 1 in 1000 treatments, the actual risk has not been quantified in large-scale, population-based studies [<span>2, 4-6</span>].</p><p>This study aimed to quantify the risk of developing SJS and TEN associated with mebendazole usage, to alleviate fears and improve the clinical basis for rational decision-making in prescribing.</p><p>This study employed a nationwide, population-based design using the Danish National Health Registries [<span>7</span>]. All Danish residents are systematically registered in the Danish Civil Registration System with a unique personal identification number, enabling precise linkage across health registries [<span>7</span>].</p><p>First, we established a cohort consisting of the entire Danish population from 1994 to 2025. Using the Danish National Prescription Register [<span>7</span>], we identified all individuals who redeemed at least one prescription for mebendazole (Anatomical Therapeutic Chemical (ATC) code P02CA01). The Danish National Patient Register was used to identify all cases of first-time diagnosis of erythema multiforme bullosum/SJS (International Classification of Diseases, 10th Revision (ICD-10) code L51.1) or TEN (ICD-10 code L51.2) during the same period. Patients assigned both diagnoses were included on equal terms with those assigned only one diagnosis. Based on this cohort, we calculated the absolute frequency of SJS/TEN following mebendazole use.</p><p>Second, we conducted a nested case–control study within the same cohort. All individuals with a first-time diagnosis of SJS or TEN were identified as cases. For each case, 100 controls were selected using risk set sampling, matched on age, sex and index date, based on data from the Danish Civil Registration System. Participants were required to have been residents in Denmark for at least 1 year prior to the index date. Mebendazole prescription retrieval was assessed for both cases and controls during two exposure windows: within 3 months and within 12 months before the index date. All prescription data were obtained from the Danish National Prescription Register identified using ATC code P02CA01.</p><p>Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). For the cohort study, we calculated the absolute frequency of SJS/TEN following mebendazole use by descriptive analysis. For the nested case–control study, we compared the proportion of mebendazole prescriptions in cases and controls and estimated the potential association between mebendazole use and the occurrence of SJS/TEN. We calculated odds ratios and 95% CI from a conditional logistic regression model. A schematic overview of the study designs is presented in Figure 1.</p><p>The study was conducted in accordance with the <i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i> policy for data studies [<span>8</span>]. The Danish Data Protection Agency (p-2024-15764) and the Danish National Board of Health (FSEID-00007077) approved this research. Danish regulations prevented the reporting of specific figures between 1 and 4 and the calculation of exact <i>p</i>-values or odds ratios to protect data confidentiality.</p><p>Between 1994 and 2025, the Danish population consisted of 9.33 million individuals, contributing 171 million person-years at risk. In this timeframe, 2.66 million prescriptions for mebendazole were redeemed by approximately 1.18 million individuals. Between 1 and 4 individuals developed SJS/TEN within 3 months after redeeming a mebendazole prescription. Thus, the observed frequency of SJS/TEN occurring within 3 months after mebendazole treatment was fewer than 1 in 450 000 prescriptions.</p><p>We identified a total of 1204 incident cases of SJS or TEN in Denmark. Of these, 1185 individuals had been Danish residents for at least 1 year prior to diagnosis and were included in the study. The average age at diagnosis was 43 years, and 46.6% of the patients were females. The controls were matched by age and sex; see Table 1.</p><p>In the 3-month window prior to diagnosis, between 1 and 4 of the cases had redeemed a prescription for mebendazole, corresponding to 0.08%–0.34% of the cases. Among the 118 500 matched controls, 275 had used mebendazole in the same period (0.23%). According to Danish data protection regulations, the exact number of exposed cases cannot be disclosed, and the resulting odds ratio cannot be calculated for this period. However, given the low number of exposed cases, any potential association is statistically insignificant.</p><p>Extending the exposure period to 12 months prior to diagnosis, 14 of the cases (1.18%) and 1295 of the controls (1.09%) had redeemed at least one mebendazole prescription. This yielded an odds ratio of 1.08 (95% CI: 0.63–1.86; <i>p</i> = 0.76), indicating no significant association between mebendazole use and the development of SJS or TEN.</p><p>This nationwide, population-based study found no significant association between mebendazole use and the development of SJS or TEN. Among more than 2.6 million redeemed prescriptions over a 31-year period, fewer than five cases of SJS/TEN were observed within 3 months after mebendazole use, corresponding to a frequency of less than 1 in 450 000 treatments. This is markedly lower than the incidence suggested in product labeling, which typically estimates the risk between 1 in 10 000 and 1 in 1000 treatments [<span>4-6</span>].</p><p>A risk as high as 1 per 1000 treated individuals for developing SJS/TEN would be particularly problematic for the indication of pinworms, as it is generally recommended to treat the entire household, including asymptomatic individuals [<span>9</span>].</p><p>While previous case reports have raised concern, especially in the context of comedication or outbreaks, our findings suggest that such events are exceedingly rare and may not reflect a causal relationship in routine clinical settings [<span>2</span>].</p><p>According to the European Medicines Agency guideline on summaries of product characteristics, frequencies of adverse reactions should be based on data from clinical trials, postauthorization safety studies and spontaneous reporting systems, where a causal relationship is at least reasonably possible [<span>10</span>]. However, it is increasingly recognized that estimates from these sources may not accurately reflect the true population risk [<span>11</span>]. Especially in cases where side effects are discovered postmarketing, it can be difficult to estimate the risk. Here, the manufacturer may choose to estimate the risk based on the ‘rule of three’, as the 95% confidence interval around 0 can be at most 3. If no cases of the new side effect were observed during the clinical trial, it cannot be excluded that there could have been three cases. The risk is thus estimated as 3 divided by the number of patients who participated in the clinical studies. Such a risk estimate will, by nature, be an absolute worst case scenario [<span>10</span>].</p><p>There are some limitations inherent to this study. First, mebendazole exposure not captured in the Danish National Prescription Register, such as purchases abroad or intrahousehold sharing of medication, could result in underestimation of true exposure. While this misclassification is unlikely to affect the calculated absolute risk observed in the cohort study, it may lead to exposure misclassification among controls in the case–control study. Second, misclassification of diagnoses is possible. The diagnosis of TEN has been validated in Danish health registries, whereas the SJS code is grouped together with erythema multiforme bullosum, which is less severe than SJS [<span>12</span>]. Consequently, the incidence of SJS may be overestimated. However, the fact that we could not report the number of cases of SJS/TEN after exposure to mebendazole according to Danish data protection legislation confirms that the risk of developing this condition is extremely rare, and it is doubtful whether there is any association at all. Finally, it should be mentioned that the study was conducted in a Danish population, which is relatively ethnically homogeneous, and whether the results translate into other populations will require further investigations. Due to the limited sample size, it was also not possible to investigate the impact of comedication, which will require future studies with larger populations.</p><p>In conclusion, our results support the continued safe use of mebendazole and provide reassuring evidence for clinicians and patients.</p><p>Ida M. Heerfordt, Espen Jimenez-Solem, Rasmus Huan Olsen and Henrik Horwitz contributed to the study conception and design. Ida M. Heerfordt, Magnus Middelboe, Rasmus Huan Olsen and Henrik Horwitz performed data collection and analysis. Ida M. Heerfordt wrote the first draft of the manuscript, and all authors reviewed and commented on subsequent versions. All authors read and approved the final manuscript.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70086","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70086","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal conditions, most often caused by adverse reactions to medication [1]. They are characterized by widespread skin necrosis and detachment of the epidermis [1]. The conditions are considered part of a disease spectrum, differentiated primarily by the extent of skin involvement [1]. It is accepted that the triggering medication is generally used within 3 months before symptom onset [1].

Mebendazole, a commonly used anthelmintic in both children and adults, has rarely been associated with SJS and TEN, primarily through isolated case series [2]. Mebendazole acts by binding to a subunit of helminthic tubulin, inhibiting microtubule formation and thereby disrupting essential cellular processes [3]. While patient labels for mebendazole cite occurrences of SJS and TEN as rare, listed as occurring in between 1 in 10 000 and 1 in 1000 treatments, the actual risk has not been quantified in large-scale, population-based studies [2, 4-6].

This study aimed to quantify the risk of developing SJS and TEN associated with mebendazole usage, to alleviate fears and improve the clinical basis for rational decision-making in prescribing.

This study employed a nationwide, population-based design using the Danish National Health Registries [7]. All Danish residents are systematically registered in the Danish Civil Registration System with a unique personal identification number, enabling precise linkage across health registries [7].

First, we established a cohort consisting of the entire Danish population from 1994 to 2025. Using the Danish National Prescription Register [7], we identified all individuals who redeemed at least one prescription for mebendazole (Anatomical Therapeutic Chemical (ATC) code P02CA01). The Danish National Patient Register was used to identify all cases of first-time diagnosis of erythema multiforme bullosum/SJS (International Classification of Diseases, 10th Revision (ICD-10) code L51.1) or TEN (ICD-10 code L51.2) during the same period. Patients assigned both diagnoses were included on equal terms with those assigned only one diagnosis. Based on this cohort, we calculated the absolute frequency of SJS/TEN following mebendazole use.

Second, we conducted a nested case–control study within the same cohort. All individuals with a first-time diagnosis of SJS or TEN were identified as cases. For each case, 100 controls were selected using risk set sampling, matched on age, sex and index date, based on data from the Danish Civil Registration System. Participants were required to have been residents in Denmark for at least 1 year prior to the index date. Mebendazole prescription retrieval was assessed for both cases and controls during two exposure windows: within 3 months and within 12 months before the index date. All prescription data were obtained from the Danish National Prescription Register identified using ATC code P02CA01.

Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). For the cohort study, we calculated the absolute frequency of SJS/TEN following mebendazole use by descriptive analysis. For the nested case–control study, we compared the proportion of mebendazole prescriptions in cases and controls and estimated the potential association between mebendazole use and the occurrence of SJS/TEN. We calculated odds ratios and 95% CI from a conditional logistic regression model. A schematic overview of the study designs is presented in Figure 1.

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for data studies [8]. The Danish Data Protection Agency (p-2024-15764) and the Danish National Board of Health (FSEID-00007077) approved this research. Danish regulations prevented the reporting of specific figures between 1 and 4 and the calculation of exact p-values or odds ratios to protect data confidentiality.

Between 1994 and 2025, the Danish population consisted of 9.33 million individuals, contributing 171 million person-years at risk. In this timeframe, 2.66 million prescriptions for mebendazole were redeemed by approximately 1.18 million individuals. Between 1 and 4 individuals developed SJS/TEN within 3 months after redeeming a mebendazole prescription. Thus, the observed frequency of SJS/TEN occurring within 3 months after mebendazole treatment was fewer than 1 in 450 000 prescriptions.

We identified a total of 1204 incident cases of SJS or TEN in Denmark. Of these, 1185 individuals had been Danish residents for at least 1 year prior to diagnosis and were included in the study. The average age at diagnosis was 43 years, and 46.6% of the patients were females. The controls were matched by age and sex; see Table 1.

In the 3-month window prior to diagnosis, between 1 and 4 of the cases had redeemed a prescription for mebendazole, corresponding to 0.08%–0.34% of the cases. Among the 118 500 matched controls, 275 had used mebendazole in the same period (0.23%). According to Danish data protection regulations, the exact number of exposed cases cannot be disclosed, and the resulting odds ratio cannot be calculated for this period. However, given the low number of exposed cases, any potential association is statistically insignificant.

Extending the exposure period to 12 months prior to diagnosis, 14 of the cases (1.18%) and 1295 of the controls (1.09%) had redeemed at least one mebendazole prescription. This yielded an odds ratio of 1.08 (95% CI: 0.63–1.86; p = 0.76), indicating no significant association between mebendazole use and the development of SJS or TEN.

This nationwide, population-based study found no significant association between mebendazole use and the development of SJS or TEN. Among more than 2.6 million redeemed prescriptions over a 31-year period, fewer than five cases of SJS/TEN were observed within 3 months after mebendazole use, corresponding to a frequency of less than 1 in 450 000 treatments. This is markedly lower than the incidence suggested in product labeling, which typically estimates the risk between 1 in 10 000 and 1 in 1000 treatments [4-6].

A risk as high as 1 per 1000 treated individuals for developing SJS/TEN would be particularly problematic for the indication of pinworms, as it is generally recommended to treat the entire household, including asymptomatic individuals [9].

While previous case reports have raised concern, especially in the context of comedication or outbreaks, our findings suggest that such events are exceedingly rare and may not reflect a causal relationship in routine clinical settings [2].

According to the European Medicines Agency guideline on summaries of product characteristics, frequencies of adverse reactions should be based on data from clinical trials, postauthorization safety studies and spontaneous reporting systems, where a causal relationship is at least reasonably possible [10]. However, it is increasingly recognized that estimates from these sources may not accurately reflect the true population risk [11]. Especially in cases where side effects are discovered postmarketing, it can be difficult to estimate the risk. Here, the manufacturer may choose to estimate the risk based on the ‘rule of three’, as the 95% confidence interval around 0 can be at most 3. If no cases of the new side effect were observed during the clinical trial, it cannot be excluded that there could have been three cases. The risk is thus estimated as 3 divided by the number of patients who participated in the clinical studies. Such a risk estimate will, by nature, be an absolute worst case scenario [10].

There are some limitations inherent to this study. First, mebendazole exposure not captured in the Danish National Prescription Register, such as purchases abroad or intrahousehold sharing of medication, could result in underestimation of true exposure. While this misclassification is unlikely to affect the calculated absolute risk observed in the cohort study, it may lead to exposure misclassification among controls in the case–control study. Second, misclassification of diagnoses is possible. The diagnosis of TEN has been validated in Danish health registries, whereas the SJS code is grouped together with erythema multiforme bullosum, which is less severe than SJS [12]. Consequently, the incidence of SJS may be overestimated. However, the fact that we could not report the number of cases of SJS/TEN after exposure to mebendazole according to Danish data protection legislation confirms that the risk of developing this condition is extremely rare, and it is doubtful whether there is any association at all. Finally, it should be mentioned that the study was conducted in a Danish population, which is relatively ethnically homogeneous, and whether the results translate into other populations will require further investigations. Due to the limited sample size, it was also not possible to investigate the impact of comedication, which will require future studies with larger populations.

In conclusion, our results support the continued safe use of mebendazole and provide reassuring evidence for clinicians and patients.

Ida M. Heerfordt, Espen Jimenez-Solem, Rasmus Huan Olsen and Henrik Horwitz contributed to the study conception and design. Ida M. Heerfordt, Magnus Middelboe, Rasmus Huan Olsen and Henrik Horwitz performed data collection and analysis. Ida M. Heerfordt wrote the first draft of the manuscript, and all authors reviewed and commented on subsequent versions. All authors read and approved the final manuscript.

The authors declare no conflicts of interest.

Abstract Image

美苯达唑与史蒂文斯-约翰逊综合征和中毒性表皮坏死松解相关的风险
史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死松解症(TEN)是罕见但潜在致命的疾病,最常见的是由药物[1]的不良反应引起的。其特征是广泛的皮肤坏死和表皮脱落。这些情况被认为是疾病谱系的一部分,主要通过皮肤受累程度来区分。目前公认的触发药物一般在症状出现前3个月内使用。甲苯达唑是儿童和成人常用的驱虫药,很少与SJS和TEN相关,主要是通过孤立病例系列[2]。甲苯咪唑通过与微管蛋白的亚基结合,抑制微管的形成,从而破坏基本的细胞过程。虽然甲苯达唑的患者标签指出SJS和TEN的发生率很少见,发生率在1 / 10000到1 / 1000之间,但实际风险尚未在大规模、基于人群的研究中量化[2,4 -6]。本研究旨在量化甲苯达唑与SJS和TEN发生的相关风险,减轻患者的恐惧,为合理处方提供临床依据。本研究采用了丹麦国家健康登记处的全国性、基于人群的设计。所有丹麦居民都有系统地在丹麦民事登记系统中登记,并具有唯一的个人识别号码,从而实现了卫生登记机构之间的精确联系[7]。首先,我们建立了一个由1994年至2025年整个丹麦人口组成的队列。使用丹麦国家处方登记册[7],我们确定了所有至少使用过一种甲苯达唑处方的个体(解剖治疗化学(ATC)代码P02CA01)。使用丹麦国家患者登记册来确定同一时期首次诊断为多形大疱性红斑/SJS(国际疾病分类,第十次修订(ICD-10)代码L51.1)或TEN (ICD-10代码L51.2)的所有病例。两种诊断的患者与只有一种诊断的患者被平等地纳入研究。基于这一队列,我们计算了甲苯达唑使用后SJS/TEN的绝对频率。其次,我们在同一队列中进行了巢式病例对照研究。所有首次诊断为SJS或TEN的个体均被确定为病例。根据丹麦民事登记系统的数据,对每个病例使用风险集抽样选择100名对照,并根据年龄、性别和索引日期进行匹配。参与者被要求在索引日期之前在丹麦居住至少1年。在两个暴露窗口:索引日期前3个月内和12个月内,对病例和对照组的甲苯达唑处方检索进行评估。所有处方数据均从使用ATC代码P02CA01识别的丹麦国家处方登记册获得。采用SAS 9.4版(SAS Institute Inc., Cary, NC)进行统计分析。在队列研究中,我们通过描述性分析计算了甲苯达唑使用后SJS/TEN的绝对频率。在巢式病例对照研究中,我们比较了病例和对照组中甲苯达唑处方的比例,并估计了甲苯达唑使用与SJS/TEN发生之间的潜在关联。我们通过条件逻辑回归模型计算比值比和95% CI。研究设计的概要概述如图1所示。这项研究是按照基本的&amp;临床药理学;数据研究的毒理学政策[b]。丹麦数据保护局(p-2024-15764)和丹麦国家卫生委员会(FSEID-00007077)批准了这项研究。丹麦条例禁止报告1至4之间的具体数字,也禁止计算确切的p值或比值比,以保护数据的机密性。1994年至2025年期间,丹麦人口为933万人,有1.71亿人年的风险。在此期间,约118万人赎回了266万张甲苯达唑处方。在服用甲苯达唑处方后的3个月内,有1至4人出现SJS/TEN。因此,观察到甲苯达唑治疗后3个月内发生SJS/TEN的频率低于45万份处方中的1份。我们在丹麦共发现1204例SJS或TEN病例。其中,1185人在确诊前在丹麦居住至少1年,并被纳入研究。平均诊断年龄43岁,女性占46.6%。对照组按年龄和性别进行匹配;见表1。在诊断前3个月窗口内,有1 ~ 4例患者曾开过甲苯达唑处方,占病例总数的0.08% ~ 0.34%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
6.50%
发文量
126
审稿时长
1 months
期刊介绍: Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信